New evidence chemotherapy can cause breast cancer to spread

Daytime anchor Robin Roberts just celebrated the five-year anniversary of her return to Good Morning America after an extended leave of absence. As you may recall, Roberts suffered from a secondary (tertiary) cancer after receiving treatment for breast cancer.

But Roberts has been lucky — these secondary cancers are typically more aggressive and, in some cases, untreatable.

Of course, the mainstream cancer industry doesn’t want to talk about how chemotherapy can cause primary cancers to spread (also known as metastasis), resulting in second — and even third — cancers.

But that’s one of the great things about science…it finds a way into the light regardless.

Chemotherapy can open doors for cancer to spread

Researchers with the Albert Einstein College of Medicine in New York recently published results of their investigation into the effects of chemotherapy on breast cancer tumors.

The researchers determined that chemotherapy can activate new ways for cancer cells to spread into the blood circulation. Specifically, they found evidence that two common types of chemo regimens used to treat breast cancer can increase the number of “doorways” in blood vessels, allowing cancer cells to spread through the circulation to other parts of the body.

There’s even a term for this process. It’s called, “chemotherapy-induced cancer cell dissemination.”

Eventually, this process can result in the development of metastatic tumors that develop at sites in the body beyond the original tumor site. Oncologists classify this type of cancer as Stage 4. It’s more aggressive and difficult to treat than the primary tumor — and often fatal.

The researchers came to this conclusion by looking at breast cancer cells extracted from humans and mice under a microscope to determine their so-called tumor microenvironment of metastasis, or TMEM, scores. The higher the TMEM score, the more likely the cancer cell will metastasize, or spread, to other sites in the body.

Turns out, some of the cancer cells treated with chemotherapy drugs had a TMEM score five-times higher than the regular cancer cells not treated with chemotherapy.

A deal with the devil

Tragically, chemotherapy doesn’t even boast a high success rate for most of the most common cancers. In fact, some experts estimate that 90 percent or more of some cancers don’t even respond to chemotherapy. Plus, chemotherapy also causes well-known side effects such as hair loss and nausea. It also causes unseen effects on the nervous system, the immune system, the brain (“chemo brain”), and even your heart, as I’ll explain tomorrow.

Yet — it remains the “first line” treatment for all cancers.

Most doctors aren’t buying it themselves, though. In fact, a survey conducted by McGill Cancer Center, in Montreal, Canada, found that 75 percent of physicians and scientists would refuse chemotherapies for themselves and their families.

More evidence to ponder

As I mentioned, this study focused on breast cancer. But the researchers said they’re also studying other types of cancer. And I have a hunch they’ll come away with the same results.

Plus, this study wasn’t even the first to demonstrate the ways chemotherapy can lead to secondary cancers. In 2010, scientists at the University of Alabama at Birmingham (UAB) received an $805,000 government grant to investigate how chemotherapy causes cancer to spread throughout the body.

That grant may seem like a lot of money, but it’s a pittance in the world of cancer research. In fact, the National Institutes of Health (NIH) doles out $33 billion every year for research on mainstream medical treatments.

This UAB grant actually came from the U.S. Department of Defense’s (DoD) Cancer Research Program. I remember when my friend, Sen. Tom Harkin (D-Iowa), now retired, came up with the idea to fund some cancer research through the Department of Defense about 20 years ago. (Sen. Harkin also nominated me to be FDA Commissioner at that time.)

Harkin said he was placing the funds in the DoD budget to get around complex Congressional rules about the budget. But I realized he was also trying to get some cancer funds out of the clutches of the medical mandarins at NIH and National Cancer Institute (NCI)!

Of course, the routine cancer screening programs — promoted vigorously by the government and mainstream cancer industry — are another big part of the problem. These programs yield a large proportion of “fake cancers” (or over-diagnoses) that would never have spread or caused death in the first place. And now we know, treating these “fake cancers” can cause further harm to the patients…and can even kill them!

Nature is full of ingredients that prevent and even block cancer activities. But the FDA refuses to allow dietary supplement manufacturers to list the anti-cancer activities of natural ingredients that have been demonstrated by scientific studies. And the FTC prohibits manufacturers from advertising the anti-cancer activities of these natural ingredients.

Dr. George Karagiannis, who led the new study, recommends monitoring women who receive chemotherapy prior to breast cancer surgery to see if the cancer is circulating. He recommends taking a small biopsy of the tumor after a few doses of chemo to test whether tumor biomarkers have increased — in which case, the chemo should be stopped.

I found it interesting the new study came from Albert Einstein College of Medicine. It was Albert Einstein himself who said that doing the same thing over and over again and expecting different results is the definition of insanity.

It’s such a tragedy.

Now, we know many cancer patients actually die from the chemotherapy — not cancer itself. So, why does mainstream medicine continue the insanity of “routine” conventional cancer treatments?

It truly boggles the mind.

For natural approaches in preventing, treating, and even reversing breast cancer (and many other types), refer to my Authentic Anti-Cancer Protocol. Simply click here to learn more or enroll today.


“Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism,” Science Translational Medicine, July 2017